In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector

Human Gene Therapy

Volumn 10, Issue 13, 1999, Pages 2245-2253

  Alden, Tord D ^a   Pittman, Debra D ^b   Hankins, Gerald R ^a   Beres, Elisa J ^a   Engh, Johnathan A ^a   Das, Subinoy ^a   Hudson, Sarah B ^a   Kerns, Kelvin M ^b   Kallmes, David F ^c   Helm, Gregory A ^a,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d University of Virginia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ENCHONDRAL OSSIFICATION; FRACTURE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; OSTEOPOROSIS; RAT; SKULL DEFECT; SPINAL CORD DISEASE; TISSUE SPECIFICITY;

ADENOVIRIDAE; ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEINS; CELL LINE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; RATS; RATS, NUDE; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, X-RAY COMPUTED; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033198839     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017220     Document Type: Article

References (51)

1. ALDEN, T.D., HANKINS, G.R., BERES, E.J., KALLMES, D.F., and HELM, G.A. (1998). Bone morphogenetic protein gene therapy for the induction of spinal arthrodesis. Neurosurg. Focus 4(2), Article 12.
2. ANDERSON, W.F. (1995). Gene therapy. Sci. Am. 273, 124-188.
3. BODEN, S.D., SCHIMANDLE, J.H., HUTTON, W.C., and CHEN, M.I. (1995). 1995 Volvo Award in basic sciences. The use of an osteoinductive growth factor for lumbar spinal fusion. II. Study of dose, carrier, and species. Spine 20, 2633-2644.
4. BRODY, S.L., METZGER, M., DANEL, C., ROSENFELD, M.A., and CRYSTAL, R.G. (1994). Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5, 821-836.
5. CANALIS, E., McCARTHY, T., and CENTRELLA, M. (1988). Growth factors and the regulation of bone remodeling. J. Clin. Invest. 81, 277-281.
6. CHENU, C., PFEILSCHIFTER, J., MUNDY, G.R., and ROODMAN, G.D. (1988). Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. U.S.A. 85, 5683-5687.
7. CONRAD, C.K., ALLEN, S.S., AFIONE, S.A., REYNOLDS, T.C., BECK, S.E., FEE-MAKI, M., BARRAZZA-ORTIZ, X., ADAMS, R., ASKIN, F.B., CARTER, B.J., GUGGINO, W.B., and FLOTTE, T.R. (1996). Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 3, 658-668.
8. COOK, S.D., and RUEGER, D.C. (1996). Osteogenic protein-1: Biology and applications. Clin. Orthoped. 324, 29-38.
9. FESTING, M.F., MAY, D., CONNORS, T.A., LOVELL, D., and SPARROW, S. (1978). An athymic nude mutation in the rat. Nature (London) 274, 365-366.
10. FISHER, K.J., JOOSS, K., ALSTON, J., YANG, Y., HAECKER, S.E., HIGH, K., PATHAK, R., RAPER, S.E., and WILSON, J.M. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med. 3, 306-312.
11. GAHERY-SEGARD, H., FARACE, F., GODFRIN, D., GASTON, J., LENGAGNE, R., TURSZ, T., BOULANGER, P., and GUILLET, J.G. (1998). Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72, 2388-2397.
12. GANNON, F.H., KAPLAN, F.S., OLMSTED, E., FINKEL, G.C., ZASLOFF, M.A., and SHORE, E. (1997). Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum. Pathol. 28, 339-343.
13. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
14. HELM, G.A., SHEEHAN, J.M., SHEEHAN, J.P., JANE, J.A., JR., DIPIERRO, C.G., SIMMONS, N.E., GILLIES, G.T., KALLMES, D.F., and SWEENEY, T.M. (1997). Utilization of type I collagen gel, demineralized bone matrix, and bone morphogenetic protein-2 to enhance autologous bone lumbar spinal fusion. J. Neurosurg. 86, 93-100.
15. JOOSS, K., YANG, Y., and WILSON, J.M. (1996). Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Ther. 7, 1555-1566.
16. JOOSS, K., TURKA, L.A., and WILSON, J.M. (1998a). Blunting of the immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5, 309-319.
17. JOOSS, K., YANG, Y., FISHER, K.J., and WILSON, J.M. (1998b). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72, 4212-4223.
18. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93, 5731-5736.
19. LEI, D., LEHMANN, M., SHELLITO, J.E., NELSON, S., SIEGLING, A., VOLK, H.D., and ROLLS, J.K. (1996). Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. Hum. Gene Ther. 7, 2273-2279.
20. LIEBER, A., HE, C.Y., MEUSE, L., HIMEDA, C., WILSON, C., and KAY, M.A. (1998). Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J. Virol. 72, 9267-9277.
21. LIEBERMAN, J.R., LE, L.Q., WU, L., FINERMAN, G.A., BERK, A., WITTE, O.N., and STEVENSON, S. (1998). Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J. Orthoped. Res. 16, 330-339.
22. MARCEL, T., and GRAUSZ, J.D. (1997). The TMC Worldwide Gene Therapy Enrollment Report, end 1996. Hum. Gene Ther. 8, 775-800.
23. McGRORY, W.J., BAUTISTA, D.S., and GRAHAM, F.L. (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163, 614-617.
24. MIKI, T., and IMAI, Y. (1996). Osteoinductive potential of freezedried, biodegradable, poly (glycolic acid-co-lactic acid) disks incorporated with bone morphogenetic protein in skull defects of rats. Int. J. Oral Maxillofac. Surg. 25, 402-406.
25. MILLER, A.D. (1992). Human gene therapy comes of age. Nature (London) 357, 455-460.
26. MIZUTANI, H. (1982). The nature of bone morphogenetic protein (BMP) fractions derived from bovine bone matrix gelatin. Clin. Orthoped. 171, 213-223.
27. MORSY, M.A., GU, M., MOTZEL, S., ZHAO, J., LIN, J., SU, Q., ALLEN, H., FRANLIN, L., PARKS, R.J., GRAHAM, F.L., KOCHANEK, S., BETT, A.J., and CASKEY, C.T. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
28. NODA, M., and CAMILLIERE, J.J. (1989). In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology 124, 2991-2994.
29. PFEILSCHIFTER, J., SEYEDIN, S.M., and MUNDY, G.R. (1988). Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. J. Clin. Invest. 82, 680-685.
30. RIEW, K.D., WRIGHT, N.M., CHENG, S., AVIOLI, L.V., and LOU, J. (1998). Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif. Tissue Int. 63, 357-360.
31. RILEY, E.H., LANE, J.M., URIST, M.R., LYONS, K.M., and LIEBERMAN, J.R. (1996). Bone morphogenetic protein-2: Biology and applications. Clin. Orthoped. 324, 39-46.
32. SANDHU, H.S., KANIM, L.E., KABO, J.M., TOTH, J.M., ZEEGEN, E.N., LIU, D., DELAMARTER, R.B., and DAWSON, E.G. (1996). Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine 21, 2115-2122.
33. SANDHU, H.S., KANIM, L.E., TOTH, J.M., KABO, J.M., LIU, D., DELAMARTER, R.B., and DAWSON, E.G. (1997). Experimental spinal fusion with recombinant human bone morphogenetic protein-2 without decortication of osseous elements. Spine 22, 1171-1180.
34. SAWCHUK, S.J., BOIVIN, G.P., DUWEL, L.E., BALL, W., BOVE, K., TRAPNELL, B., and HIRSCH, R. (1996). Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. Hum. Gene Ther. 7, 499-506.
35. SCHIMANDLE, J.H., BODEN, S.D., and HUTTON, W.C. (1995). Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 20, 1326-1337.
36. SHAFRITZ, A.B., SHORE, E.M., GANNON, F.H., ZASLOFF, M.A., TAUB, R., MUENKE, M., and KAPLAN, F.S. (1996). Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N. Engl. J. Med. 335, 555-561.
37. SHEEHAN, J.P., KALLMES, D.F., SHEEHAN, J.M., JANE, J.A., JR., FERGUS, A.H., DIPIERRO, C.G., SIMMONS, N.E., MAKEL, D.D., and HELM, G.A. (1996). Molecular methods of enhancing lumbar spine fusion. Neurosurgery 39, 548-554.
38. SIMON, R.H., ENGELHARDT, J.F., YANG, Y., ZEPEDA, M., WEBER-PENDLETON, S., GROSSMAN, M., and WILSON, J.M. (1993). Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Toxicity study. Hum. Gene Ther. 4, 771-780.
39. SWEENEY, T.M., OPPERMAN, L.A., PERSING, J.A., and OGLE, R.C. (1995). Repair of critical size rat calvarial defects using extracellular matrix protein gels. J. Neurosurg. 83, 710-715.
40. SULLIVAN, D.E., DASH, S., DU, H., HIRAMATSU, N., AYDIN, F., KOLLS, J., BLANCHARD, J., BASKIN, G., and GERBER, M.A. (1997). Liver-directed gene transfer in non-human primates. Hum. Gene Ther. 8, 1195-1206.
41. TAKAGI, K., and URIST, M.R. (1982a). The reaction of the dura to bone morphogenetic protein (BMP) in repair of skull defects. Ann. Surg. 196, 100-109.
42. TAKAGI, K., and URIST, M.R. (1982b). The role of bone marrow in bone morphogenetic protein-induced repair of femoral massive diaphyseal defects. Clin. Orthoped. 171, 224-231.
43. THIES, R.S., BAUDUY, M., ASHTON, B.A., KURTZBERG, L., WOZNEY, J.M., and ROSEN, V. (1992). Recombinant human bone morphogenic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130, 1303-1318.
44. TRAPNELL, B.C., and GORZIGLIA, M. (1994). Gene therapy using adenoviral vectors. Curr. Opin. Biotechnol. 5, 617-625.
45. URIST, M.R. (1965). Bone: Formation by autoinduction. Science 150, 893-899.
46. YANG, Y., ERTL, H.C., and WILSON, J.M. (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1, 433-442.
47. YANG, Y., LI, Q., ERTL, H.C., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
48. YANG, Y., SU, Q., and WILSON, J.M. (1996). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70, 7209-7210.
49. YASKO, A.W., LANE, J.M., FELLINGER, E.J., ROSEN, V., WOZNEY, J.M., and WANG, E.A. (1992). The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J. Bone Joint Surg. Am. 74, 659-670.
50. YEI, S., MITTEREDER, N., WERT, S., WHITSETT, J.A., WILMOTT, R.W., and TRAPNELL, B.C. (1994). In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum. Gene Ther. 5, 731-744.
51. ZHANG, H.G., ZHOU, T., YANG, P., EDWARDS, C.K., III, CURIEL, D.T., and MOUNTZ, J.D. (1998). Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum. Gene Ther. 9, 1875-1884.